1. Home
  2. BMEA vs ATLX Comparison

BMEA vs ATLX Comparison

Compare BMEA & ATLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.40

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Logo Atlas Lithium Corporation

ATLX

Atlas Lithium Corporation

HOLD

Current Price

$4.39

Market Cap

124.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
ATLX
Founded
2017
2011
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
138.1M
124.5M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
BMEA
ATLX
Price
$1.40
$4.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
1
Target Price
$9.83
$12.00
AVG Volume (30 Days)
1.2M
909.6K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
47.08
EPS
N/A
N/A
Revenue
N/A
$92,491.00
Revenue This Year
N/A
$64,564.67
Revenue Next Year
N/A
$785.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$3.60
52 Week High
$3.07
$8.25

Technical Indicators

Market Signals
Indicator
BMEA
ATLX
Relative Strength Index (RSI) 45.33 44.07
Support Level $1.23 $3.97
Resistance Level $1.45 $5.04
Average True Range (ATR) 0.10 0.33
MACD 0.00 -0.07
Stochastic Oscillator 47.57 14.35

Price Performance

Historical Comparison
BMEA
ATLX

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About ATLX Atlas Lithium Corporation

Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.

Share on Social Networks: